Eloralintide
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Eli Lilly · Phase 1 · Not yet recruiting · Enrollment 60
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Macupatide + placebo | n/r | n/r | n/r | n/r | n/r |
| Eloralintide + placebo | n/r | n/r | n/r | n/r | n/r |
| Macupatide Dose A + Eloralintide | n/r | n/r | n/r | n/r | n/r |
| Macupatide Dose B + Eloralintide | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.